Sign up
Pharma Capital

Avacta boss Alastair Smith anticipating 2018 to be a very significant year

Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT) tells Proactive the past year had been one of significant progress – both for the development of a potential drug based on its platform and its use by other customers in research and diagnostics.

Smith says they've made excellent progress with their potential cancer drug, a PD-L1 inhibitor that helps the body’s immune system to tackle the disease.

They're expecting first-in-man clinical trials to kick-off in 2019.

 

View full AVCT profile

Avacta Group Plc Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.